Cargando…
Duality of B Cell-CXCL13 Axis in Tumor Immunology
Tumor immunity is a rapidly evolving area of research consisting of many possible permutations of immune cell tumor interactions that are dependent upon cell type, tumor type, and stage in tumor progression. At the same time, the majority of cancer immunotherapies have been focused on modulating the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609404/ https://www.ncbi.nlm.nih.gov/pubmed/33193299 http://dx.doi.org/10.3389/fimmu.2020.521110 |
_version_ | 1783605026304819200 |
---|---|
author | Rubio, Angel J. Porter, Tyrone Zhong, Xuemei |
author_facet | Rubio, Angel J. Porter, Tyrone Zhong, Xuemei |
author_sort | Rubio, Angel J. |
collection | PubMed |
description | Tumor immunity is a rapidly evolving area of research consisting of many possible permutations of immune cell tumor interactions that are dependent upon cell type, tumor type, and stage in tumor progression. At the same time, the majority of cancer immunotherapies have been focused on modulating the T cell-mediated antitumor immune response and have largely ignored the potential utility that B cells possess with respect to tumor immunity. Therefore, this motivated an exploration into the role that B cells and their accompanying chemokine, CXCL13, play in tumor immunity across multiple tumor types. Both B cells and CXCL13 possess dualistic impacts on tumor progression and tumor immunity which is furthered detail in this review. Specifically, various B cells subtypes are able to suppress or enhance several important immunological functions. Paradoxically, CXCL13 has been shown to drive several pro-growth and invasive signaling pathways across multiple tumor types, while also, correlating with improved survival and immune cell tumor localization in other tumor types. Potential tools for better elucidating the mechanisms by which B cells and CXCL13 impact the antitumor immune response are also discussed. In addition, multiples strategies are proposed for modulating the B cell-CXCL13 axis for cancer immunotherapies. |
format | Online Article Text |
id | pubmed-7609404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76094042020-11-13 Duality of B Cell-CXCL13 Axis in Tumor Immunology Rubio, Angel J. Porter, Tyrone Zhong, Xuemei Front Immunol Immunology Tumor immunity is a rapidly evolving area of research consisting of many possible permutations of immune cell tumor interactions that are dependent upon cell type, tumor type, and stage in tumor progression. At the same time, the majority of cancer immunotherapies have been focused on modulating the T cell-mediated antitumor immune response and have largely ignored the potential utility that B cells possess with respect to tumor immunity. Therefore, this motivated an exploration into the role that B cells and their accompanying chemokine, CXCL13, play in tumor immunity across multiple tumor types. Both B cells and CXCL13 possess dualistic impacts on tumor progression and tumor immunity which is furthered detail in this review. Specifically, various B cells subtypes are able to suppress or enhance several important immunological functions. Paradoxically, CXCL13 has been shown to drive several pro-growth and invasive signaling pathways across multiple tumor types, while also, correlating with improved survival and immune cell tumor localization in other tumor types. Potential tools for better elucidating the mechanisms by which B cells and CXCL13 impact the antitumor immune response are also discussed. In addition, multiples strategies are proposed for modulating the B cell-CXCL13 axis for cancer immunotherapies. Frontiers Media S.A. 2020-10-21 /pmc/articles/PMC7609404/ /pubmed/33193299 http://dx.doi.org/10.3389/fimmu.2020.521110 Text en Copyright © 2020 Rubio, Porter and Zhong. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Rubio, Angel J. Porter, Tyrone Zhong, Xuemei Duality of B Cell-CXCL13 Axis in Tumor Immunology |
title | Duality of B Cell-CXCL13 Axis in Tumor Immunology |
title_full | Duality of B Cell-CXCL13 Axis in Tumor Immunology |
title_fullStr | Duality of B Cell-CXCL13 Axis in Tumor Immunology |
title_full_unstemmed | Duality of B Cell-CXCL13 Axis in Tumor Immunology |
title_short | Duality of B Cell-CXCL13 Axis in Tumor Immunology |
title_sort | duality of b cell-cxcl13 axis in tumor immunology |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609404/ https://www.ncbi.nlm.nih.gov/pubmed/33193299 http://dx.doi.org/10.3389/fimmu.2020.521110 |
work_keys_str_mv | AT rubioangelj dualityofbcellcxcl13axisintumorimmunology AT portertyrone dualityofbcellcxcl13axisintumorimmunology AT zhongxuemei dualityofbcellcxcl13axisintumorimmunology |